治疗急性髓系白血病新药:FLT3抑制剂 gilteritinib

A new drug in treating acute myeloid leukemia: FLT3 inhibitor gilteritinib

FMS样酪氨酸激酶3 (FLT3)的基因在造血干细胞增殖、分化及存活方面发挥重要作用。FLT3内部串联重复突变(FLT3-ITD)在急性髓系白血病(AML)中常见,且与迅速复发及生存率低密切相关。gilteritinib (Gil)为新型FLT3抑制剂,由Astellas制药公司生产,于2018年11月经美国食品和药物管理局批准用于FLT3突变型复发难治性AML的治疗。临床试验表明对其他FLT3抑制剂耐药的AML患者,采用Gil治疗仍可取得较好疗效,其最常见的不良反应包括肌肉痛、关节痛、转氨酶升高、疲劳、发热等。

The FMS-like tyrosine kinase 3(FLT3)gene plays an important role in hematopoietic stem cell proliferation,differentiation and survival.Internal tandem duplication mutations in FLT3(FLT3-ITD)are common in acute myeloid leukaemia(AML)and are associated with rapid relapse and low overall survival.Gilteritinib(Gil)is a novel FLT3 inhibitor developed by Astellas Pharma Inc.It has been approved for the treatment of FLT3 mutant relapsed refractory AML by the U.S.Food and Drug Administration on November,2018.Clinical trials indicate that patients with AML who are resistant to other FLT3 inhibitors with Gil still achieve good results.The most common adverse reactions include myalgia,arthralgia,transaminase increase,fatigue,fever and so on.